MediNatura™ Incorporated, a Delaware Corporation headquartered in greater Philadelphia, announced today that the company has become the exclusive importer for the following injection solutions: Traumeel®, Zeel®, LymphomyosotX®, Spascupreel®, Neuralgo-Rheum® and Engystol®.
MediNatura™ is particularly excited to offer Traumeel® and Zeel®, given the recent clinical study results presented at the 2014 American College of Rheumatology (ACR) Annual Meeting. The study results demonstrated that co-administered Traumeel® (Tr14) and Zeel® (Ze14) intra-articular (IA) injections are safe and effective treatments for moderate to severe pain associated with knee osteoarthritis (OA) versus IA placebo. Specifically, these results showed statistically and clinically relevant pain relief for knee OA. The results were presented at ACR by Carlos Lozada, M.D., who together with Roland Moskowitz, M.D., helped design the trial. The abstract is available here: http://acrabstracts.org/abstracts/a-multi-center-double-blind-randomized-controlled-trial-db-rct-to-evaluate-the-effectiveness-and-safety-of-co-administered-traumeel-tr14-and-zeel-ze14-intra%e2%80%91articular-ia/.
"This study provides clinical evidence to support knee OA treatment with Traumeel® and Zeel®, providing an additional treatment option especially important for those patients who cannot tolerate non-steroidal anti-inflammatory drugs (NSAIDs), are not candidates for corticosteroid treatment or do not respond to other therapies," noted study co-investigator Roland Moskowitz, M.D., Clinical Professor of Medicine, University Hospitals, Case Medical Center.
High-impact exercise boosts bone density without harming knee health in postmenopausal women